HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hyo Jeong Hong Selected Research

Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)

1/2021An antibody against L1 cell adhesion molecule inhibits cardiotoxicity by regulating persistent DNA damage.
10/2019Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
5/2017L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation.
1/2017Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
1/2016Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM.
4/2012A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model.
3/2012L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells.
10/2011L1 cell adhesion molecule as a novel independent poor prognostic factor in gallbladder carcinoma.
4/2011The cell adhesion molecule L1 promotes gallbladder carcinoma progression in vitro and in vivo.
1/2011Structural mechanism of the antigen recognition by the L1 cell adhesion molecule antibody A10-A3.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hyo Jeong Hong Research Topics

Disease

18Neoplasms (Cancer)
10/2019 - 03/2006
8Cholangiocarcinoma
10/2019 - 12/2009
4Infections
07/2021 - 02/2008
4Carcinoma (Carcinomatosis)
10/2011 - 03/2006
2Neoplasm Metastasis (Metastasis)
05/2011 - 04/2011
1Fibrosis (Cirrhosis)
01/2021
1Cardiotoxicity
01/2021
1Cardiomyopathies (Cardiomyopathy)
01/2021
1Cholera
11/2020
1COVID-19
07/2020
1Colonic Neoplasms (Colon Cancer)
03/2015
1Colorectal Neoplasms (Colorectal Cancer)
03/2015
1Breast Neoplasms (Breast Cancer)
06/2014
1Stomach Neoplasms (Stomach Cancer)
11/2013
1Myocardial Infarction
05/2011
1Ischemia
05/2011
1Diabetic Retinopathy (Retinopathy, Diabetic)
05/2011
1Carcinoid Tumor (Carcinoid)
02/2009
1Neuroendocrine Tumors (Neuroendocrine Tumor)
02/2009
1Wounds and Injuries (Trauma)
03/2006
1Adenocarcinoma
03/2006
1Vascular Remodeling
02/2005

Drug/Important Bio-Agent (IBA)

13Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA
01/2021 - 02/2009
6Proteins (Proteins, Gene)FDA Link
07/2020 - 03/2006
4Monoclonal AntibodiesIBA
07/2021 - 02/2009
4AntibodiesIBA
07/2020 - 02/2008
3Therapeutic UsesIBA
01/2017 - 03/2006
3Glycoproteins (Glycoprotein)IBA
03/2015 - 03/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 11/2013
2Trastuzumab (Herceptin)FDA Link
01/2018 - 11/2013
2Cisplatin (Platino)FDA LinkGeneric
01/2017 - 03/2012
2AntigensIBA
06/2014 - 07/2010
2tumor-associated antigen 72IBA
12/2007 - 03/2006
1Neutralizing AntibodiesIBA
07/2021
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021
1LipopolysaccharidesIBA
11/2020
1Lipid AIBA
11/2020
1O Antigens (O Antigen)IBA
11/2020
1Polysaccharides (Glycans)IBA
11/2020
1SARS-CoV-2 spike proteinIBA
07/2020
1EpitopesIBA
07/2020
1Biomarkers (Surrogate Marker)IBA
10/2019
11,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
10/2019
1Chelating AgentsIBA
10/2019
1Glucose (Dextrose)FDA LinkGeneric
10/2019
1AcidsIBA
10/2019
1sodium-bile acid cotransporterIBA
08/2018
1Cetuximab (Erbitux)FDA Link
01/2018
1Pharmaceutical PreparationsIBA
01/2017
1Cell Adhesion MoleculesIBA
01/2017
1GemcitabineFDA Link
01/2017
1Angiogenesis InhibitorsIBA
03/2015
1EndostatinsIBA
03/2015
1RNA (Ribonucleic Acid)IBA
06/2014
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2013
1Epidermal Growth Factor (EGF)IBA
11/2013
1Bevacizumab (Avastin)FDA Link
11/2013
1afliberceptIBA
11/2013
1Vascular Endothelial Growth Factor BIBA
11/2013
1Immunoglobulin G (IgG)IBA
04/2012
1ErbB Receptors (EGF Receptor)IBA
03/2012
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
02/2011
1Small Interfering RNA (siRNA)IBA
07/2010
1Hepatitis B Surface Antigens (HBsAg)FDA Link
02/2008
1B72.3 antibodyIBA
12/2007
1Thrombopoietin (c-mpl Ligand)IBA
04/2006
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
03/2006
1Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
03/2006
1Cartilage Oligomeric Matrix ProteinIBA
03/2006
1TIE-2 Receptor (Receptor, TIE 2)IBA
02/2005
1Angiopoietin-2IBA
02/2005

Therapy/Procedure

7Drug Therapy (Chemotherapy)
10/2019 - 04/2006
6Therapeutics
01/2021 - 03/2006
3Radiotherapy
10/2019 - 04/2012
1Radioimmunotherapy
10/2019
1Precision Medicine
10/2019